These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17520094)

  • 1. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
    Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
    Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
    Jagtap P; Szabó C
    Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
    Makogon NV; Aleksieieva IM
    Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
    Sodhi RK; Singh N; Jaggi AS
    Vascul Pharmacol; 2010; 53(3-4):77-87. PubMed ID: 20633699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP as a Drug Target for the Therapy of Diabetic Cardiovascular Dysfunction.
    Szabo C
    Drug News Perspect; 2002 May; 15(4):197-205. PubMed ID: 12677203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
    Putt KS; Hergenrother PJ
    Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
    Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
    Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
    Masutani M; Nakagama H; Sugimura T
    Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
    Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
    Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ; Szabó C
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward specific functions of poly(ADP-ribose) polymerase-2.
    Yélamos J; Schreiber V; Dantzer F
    Trends Mol Med; 2008 Apr; 14(4):169-78. PubMed ID: 18353725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoprotective effect of gallotannin in oxidatively stressed HaCaT keratinocytes: the role of poly(ADP-ribose) metabolism.
    Bakondi E; Bai P; Erdélyi K; Szabó C; Gergely P; Virág L
    Exp Dermatol; 2004 Mar; 13(3):170-8. PubMed ID: 14987257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.